Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004
- PMID: 16896144
Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004
Abstract
During 1996 through 2004, 29 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been reported worldwide; 17 were fatal. Stress-dose corticosteroid (SDS) therapy has recently been found to improve survival among patients with septic shock but benefit for the treatment of YEL-AVD patients in septic shock is unknown. We retrospectively reviewed medical records of 11 U.S. YEL-AVD cases reported to the Vaccine Adverse Event Reporting System (VAERS) from 1996 through 2004. Four of 11 case-patients received SDS; 3 of these 4 (75%) survived. Seven patients did not receive SDS and 2 (29%) survived. Altered mental status was documented on admission for 5 of the 11 patients; 4 of these 5 did not receive SDS and died, whereas one received SDS and survived. The use of stress-dose steroids might be a factor that influenced the survival of these YEL-AVD patients and should be further evaluated in the management of both YEL-AVD and wild-type yellow fever septic shock.
Similar articles
-
Viscerotropic disease following yellow fever vaccination in Peru.Vaccine. 2009 Oct 9;27(43):5974-81. doi: 10.1016/j.vaccine.2009.07.082. Epub 2009 Aug 11. Vaccine. 2009. PMID: 19679215
-
Yellow fever-associated viscerotropic disease in Barcelona, Spain.J Travel Med. 2008 May-Jun;15(3):202-5. doi: 10.1111/j.1708-8305.2008.00209.x. J Travel Med. 2008. PMID: 18494699 Review.
-
Acute viscerotropic disease following vaccination against yellow fever.Trans R Soc Trop Med Hyg. 2007 Oct;101(10):967-71. doi: 10.1016/j.trstmh.2007.06.013. Epub 2007 Jul 31. Trans R Soc Trop Med Hyg. 2007. PMID: 17669451 Review.
-
Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.Vaccine. 2005 May 9;23(25):3256-63. doi: 10.1016/j.vaccine.2005.01.089. Vaccine. 2005. PMID: 15837230
-
Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):989-93. MMWR Morb Mortal Wkly Rep. 2002. PMID: 12455906
Cited by
-
Advancing molecular modeling and reverse vaccinology in broad-spectrum yellow fever virus vaccine development.Sci Rep. 2024 May 12;14(1):10842. doi: 10.1038/s41598-024-60680-9. Sci Rep. 2024. PMID: 38735993 Free PMC article.
-
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.Front Immunol. 2020 Jul 17;11:1382. doi: 10.3389/fimmu.2020.01382. eCollection 2020. Front Immunol. 2020. PMID: 32765496 Free PMC article.
-
What Does the Future Hold for Yellow Fever Virus? (II).Genes (Basel). 2018 Aug 21;9(9):425. doi: 10.3390/genes9090425. Genes (Basel). 2018. PMID: 30134625 Free PMC article. Review.
-
Yellow fever vaccine-associated viscerotropic disease: current perspectives.Drug Des Devel Ther. 2016 Oct 12;10:3345-3353. doi: 10.2147/DDDT.S99600. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27784992 Free PMC article. Review.
-
Occurrence of Autoimmune Diseases Related to the Vaccine against Yellow Fever.Autoimmune Dis. 2014;2014:473170. doi: 10.1155/2014/473170. Epub 2014 Oct 22. Autoimmune Dis. 2014. PMID: 25405025 Free PMC article. Review.